INSACOG: First case of Omicron subvariant BA.4, BA.5 in India
Hyderabad: The Indian SARS-CoV-2 Genomics Consortium (INSACOG) has confirmed the first case of BA.4 and BA.5 variants of Covid-19 in India.
"A-19-year-old female in Tamil Nadu has been found infected with the BA.4 variant of SARS-CoV-2," said INSACOG in a statement, adding that the patient has shown only mild clinical symptoms and has been fully vaccinated and has no travel history.
Also Read:Study explains faster transmission of the Omicron virus and why third dose might be needed
Before this, a South African traveller was reported positive for the BA.4 variant on arrival at Hyderabad airport, added INSACOG.
Meanwhile, a male from Telangana has been tested positive for the BA.5 variant, according to INSACOG.
"An 80-year-old male in Telangana has tested positive for the BA.5 variant SARS-CoV-2. The patient has shown only mild clinical symptoms and has been fully vaccinated with no travel history," the Genomics Consortium body in the statement.
The genome sequencing body further said that the contact tracing of the BA.4 and BA.5 patients is being undertaken as a precautionary measure.
"BA.4 and BA.5 are sub-variants of the Omicron variant circulating globally. These were reported first from South Africa earlier this year and are now reported from several other countries," said INSACOG, adding these variants have not been associated with disease severity or increased hospitalisation.
In South Africa, the two sub-variants of Omicron i.e. BA.4 and BA.5 have contributed to the fifth wave of Covid-19. These two variants of Omicron have been declared as 'variants of concern' by The European Centre for Disease Control and Prevention.
India too is unlikely to see an increase in mortality with the current variant, say experts, because of the hybrid immunity conferred by vaccination and previous infection, including with the BA.1 and BA.2 sub-variants of Omicron during the third wave of Covid-19 cases reports The Indian Express.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.